SynthesisBMC cancer2026

Meta-analysis reveals pathological complete response benefits from neoadjuvant immuno-chemotherapy combination in patients with HER2-negative breast cancer.

Yuhan Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.